Clinical Trial Update: A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System [Phase 1]

View source ↗

Summary

Phase 1 trial investigating safety and activity of a novel TNFR2 inhibitor in adults with non-Hodgkin lymphoma, including cutaneous T-cell lymphoma, with status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• TNFR2 inhibitor (unnamed)

Snippet

Sponsor: Boston Immune Technologies and Therapeutics | Conditions: NHL, Cutaneous T Cell Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING